169 related articles for article (PubMed ID: 31308667)
1. Cognitive symptoms in major depressive disorder: associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China.
Wang G; Si TM; Li L; Fang Y; Wang CX; Wang LN; Tan KHX; Ettrup A; Eriksen HF; Luo S; Ge L
Neuropsychiatr Dis Treat; 2019; 15():1723-1736. PubMed ID: 31308667
[No Abstract] [Full Text] [Related]
2. Impact of Cognitive Symptoms on Health-Related Quality of Life and Work Productivity in Chinese Patients with Major Depressive Disorder: Results from the PROACT Study.
Wang G; Tan KHX; Ren H; Hammer-Helmich L
Neuropsychiatr Dis Treat; 2020; 16():749-759. PubMed ID: 32214816
[TBL] [Abstract][Full Text] [Related]
3. Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: Cross-sectional analysis of baseline data from PERFORM-J.
Sumiyoshi T; Watanabe K; Noto S; Sakamoto S; Moriguchi Y; Tan KHX; Hammer-Helmich L; Fernandez J
J Affect Disord; 2019 Nov; 258():172-178. PubMed ID: 31426015
[TBL] [Abstract][Full Text] [Related]
4. Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder.
Sumiyoshi T; Hoshino T; Mishiro I; Hammer-Helmich L; Ge H; Moriguchi Y; Fujikawa K; Fernandez JL
J Affect Disord; 2022 Jan; 296():95-102. PubMed ID: 34597893
[TBL] [Abstract][Full Text] [Related]
5. Validation and Functional Relevance of the Short Form of the Perceived Deficits Questionnaire for Depression for Japanese Patients with Major Depressive Disorder.
Sumiyoshi T; Uchida H; Watanabe K; Oosawa M; Ren H; Moriguchi Y; Fujikawa K; Fernandez J
Neuropsychiatr Dis Treat; 2022; 18():2507-2517. PubMed ID: 36353465
[TBL] [Abstract][Full Text] [Related]
6. Relationship of Subjective Cognitive Impairment with Psychosocial Function and Relapse of Depressive Symptoms in Patients with Major Depressive Disorder: Analysis of Longitudinal Data from PERFORM-J.
Sumiyoshi T; Watanabe K; Noto S; Sakamoto S; Moriguchi Y; Hammer-Helmich L; Fernandez J
Neuropsychiatr Dis Treat; 2021; 17():945-955. PubMed ID: 33814911
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Cognitive Impairment on the Prognosis of Major Depressive Disorder.
Zhang BH; Feng L; Feng Y; Xin LM; Zhu XY; Tan YL; Wang G
J Nerv Ment Dis; 2020 Sep; 208(9):683-688. PubMed ID: 32433202
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
Almeida SS; Christensen MC; Simonsen K; Adair M
J Psychopharmacol; 2023 Mar; 37(3):279-288. PubMed ID: 36377523
[TBL] [Abstract][Full Text] [Related]
9. Reliability and validity of Chinese version of perceived deficits questionnaire for depression in patients with MDD.
Shi C; Wang G; Tian F; Han X; Sha S; Xing X; Yu X
Psychiatry Res; 2017 Jun; 252():319-324. PubMed ID: 28314227
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study.
Polosan M; Rabbani M; Christensen MC; Simonsen K; Ren H
Neuropsychiatr Dis Treat; 2022; 18():1963-1974. PubMed ID: 36068858
[TBL] [Abstract][Full Text] [Related]
11. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea.
Cumbo E; Adair M; Åstrom DO; Christensen MC
Front Aging Neurosci; 2022; 14():1037816. PubMed ID: 36698860
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.
Mattingly GW; Ren H; Christensen MC; Katzman MA; Polosan M; Simonsen K; Hammer-Helmich L
Front Psychiatry; 2022; 13():824831. PubMed ID: 35356713
[TBL] [Abstract][Full Text] [Related]
14. Association between baseline cognitive symptoms and the subsequent presenteeism and global function in patients with major depressive disorder.
Watanabe K; Marumoto T; Ge H; Moriguchi Y; Fujikawa K; Fernandez JL
J Psychiatr Res; 2022 Oct; 154():324-331. PubMed ID: 36027860
[TBL] [Abstract][Full Text] [Related]
15. Residual cognitive and psychosocial functional impairment in outpatients in Greece who responded to conventional antidepressant monotherapy treatments for major depressive disorder (MDD).
Papalexi E; Galanopoulos A; Roukas D; Argyropoulos I; Michopoulos I; Douzenis A; Gkolia I; Fotiadis P; Kontis D; Zervas IM
J Affect Disord; 2022 Oct; 314():185-192. PubMed ID: 35817305
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with objective and subjective cognitive impairment in Chinese patients with acute major depressive disorder.
Zhu N; Tong J; Pei Y; Zhang J; Sun X
BMC Psychiatry; 2023 May; 23(1):348. PubMed ID: 37208711
[TBL] [Abstract][Full Text] [Related]
17. Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder in Japan (PERFORM-J): Protocol for a Prospective Cohort Study.
Sumiyoshi T; Watanabe K; Noto S; Sakamoto S; Moriguchi Y; Okamoto S
JMIR Res Protoc; 2018 Jun; 7(6):e161. PubMed ID: 29941418
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study.
Haro JM; Hammer-Helmich L; Saragoussi D; Ettrup A; Larsen KG
Neuropsychiatr Dis Treat; 2019; 15():2313-2323. PubMed ID: 31616147
[TBL] [Abstract][Full Text] [Related]
19. Associations between increased circulating endothelial progenitor cell levels and anxiety/depressive severity, cognitive deficit and function disability among patients with major depressive disorder.
Liou YJ; Chen MH; Hsu JW; Huang KL; Huang PH; Bai YM
Sci Rep; 2021 Sep; 11(1):18221. PubMed ID: 34521977
[TBL] [Abstract][Full Text] [Related]
20. Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder.
Lam RW; Lamy FX; Danchenko N; Yarlas A; White MK; Rive B; Saragoussi D
Neuropsychiatr Dis Treat; 2018; 14():2861-2877. PubMed ID: 30464471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
